The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Idiopathic Pulmonary Arterial Hypertension

Interventions

DRUG

(Pyr1)apelin-13

(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups

DRUG

Saline

Trial Locations (2)

Hammersmith Hospital, Imperial College London, London

Imperial College Healthcare NHS Trust, London

All Listed Sponsors

lead

Imperial College London

OTHER

NCT01590108 - The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects | Biotech Hunter | Biotech Hunter